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ABSTRACT
The human papillomavirus (HPV) oncogenes, E6 and E7, are believed
to contribute to the development of cervical cancers in women infected
with certain HPV genotypes, most notably HPV-16 and HPV-18. Given
their expression in tumor tissue, E6 and E7 have been implicated as
potential tumor-specific antigens. We have examined an HPV-16 E6- and
E7-transgenic mouse lineage for immune responses to these viral onco-
proteins. Mice in this lineage express the HPV-16 E6 and E7 genes in their
skin and eyes, and on aging, these mice frequently develop squamous cell
carcinomas and lenticular tumors. Young transgenic mice, which had
measurable E7 protein in the eye but not in the skin, were immunologi-
cally naive to E7 protein. They mounted an immune response to E7 on
immunization comparable to that of nontransgenic controls, suggesting a
lack of immune tolerance to this protein. Older line 19 mice, which are
susceptible to skin disease associated with transcription of the E6 and E7
open reading frames, had measurable E7 protein in their skin. These older
transgenic mice spontaneously developed antibody responses to endoge
nous E7 protein, particularly in association with skin disease. Also de
tected in older mice were delayed-type hypersensitivity responses to E7.
These finding parallel the humoral immune response to E7 protein in
patients with HPV-associated cervical cancer and suggest that line 19 mice
may provide a model for studying the immunobiology of HPV-associated
INTRODUCTION
A majority of cervical cancers contain HPV3 DNA, and between 60
and 80% of these contain DNA from the HPV-16 genotype (1),
commonly integrated within the cellular genome. In HPV DNA-
positive cervical cancers, transcription of the E6 and E7 ORFs of HPV
is observed, and a critical role for these viral gene products in cervical
cancer can be inferred from the preservation in each cancer of these
ORFs (2). Additional evidence for the role of E6 and E7 comes from
the observation that expression of the E6 and E7 ORFs in primary
human epithelial cell cultures facilitates their immortalization (3).
Furthermore, mice transgenic for E6 and E7 develop epidermal
hyperplasia (4, 5) and are at increased risk of epithelial tumor
development (6).
That E6 and E7 are expressed in cervical cancers indicates that
these viral gene products are potential tumor-specific antigens that
might be the target of host-protective immune responses. The
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increased incidence of cervical cancer in immunosuppressed renal
transplant recipients (7) and in patients with HIV-AIDS (8, 9)
suggests that a protective host response occurs in immunocompe-
tent patients. Antibody to the E7 ORF of HPV-16 has been dem
onstrated more frequently in patients with HPV-16-associated can
cer than in control subjects not expected to be exposed to HPV-16
(10); this is observed particularly in patients with invasive HPV-
16-associated tumors. A role of E7-directed immune responses in
tumor protection has been raised by studies in which animals
immunized against E7 acquired resistance to challenge with tumor
cells expressing E7 (11). We have sought to assess the role of
E7-specific immunity in a relevant mouse model that closely
approximates the natural course of disease seen with human cer
vical cancer, and in which the papillomaviral oncogenes play a
causative role in tumorigenesis. Several lines of mice transgenic
for the HPV-16 E6 and E7 ORFs driven from the aA-crystallin
promoter have been described recently (4). One of these lines of
mice (aAcryHPV16E6/E7-linel9) develops a skin pathology in
cluding hair loss, dermal thickening, papilloma development, and
eventual skin cancer associated with increased levels of E6 and E7
mRNAs in the affected skin (12). This disease begins to appear at
3 months of age; by 1 year approximately 50% have abnormal skin.
In the current study, we have characterized immunity to HPV-16
E7 protein in these mice and the relationship between any observed
tolerance of, or immunity to, E7 and the development of the skin
disease. As seen in cervical cancer patients, these mice were found
to develop humoral and cellular immune responses against E7
protein, and this correlated with the presence of transgene-induced
skin disease. These findings indicate that these HPV-16 transgenic
mice may provide a useful model for studying the immunobiology
of HPV-associated neoplasia.
MATERIALS AND METHODS
Mice. Nontransgenic FVB mice and aAcryHPV16E6/E7-line 19 mice
derived from FVB mice and homozygous for a transgene that includes the
E6 and E7 ORFs of HPV-16, driven by the aA-crystallin promoter, were held
in standard American Association for Accreditation of Laboratory Animal
Care approved mouse rooms under specific pathogen-free conditions.
Proteins and Peptides. A series of overlapping 18-26-mer peptides span
ning the 98-amino acid predicted sequence of the E7 protein of HPV-16 (Fig.
1) were synthesized with the use of F-moc chemistry on an Applied Biosys-
tems AB431 synthesizer (Applied Biosystems, Foster City, CA) as described
previously (13). Synthetic peptides BT12D (DRAHYNIVTFCCKCDQAEP-
DAGIDGPAGEYMLD: single letter code) containing three B epitopes and a
T-helper epitope from HPV-16 E7, GF110 (TRKSIRIQRGPDRAHYNIVTF-
CCKCD), including a HIV-1 gpl20 B epitope and a T-helper epitope from
HPV-16 E7, and GF22 (QDIVLHLEPQNEIPVDLL), which includes a B
epitope from HPV-18 E7 protein, were synthesized similarly. Peptides were
purified by HPLC and analyzed as described previously (13). An HPV-16 E7
GST fusion protein was prepared in Escherichia coli and purified as described
(14). The bacterially produced fusion protein MS2-E7(15) was prepared from
E. coli as described (16). Baculovirus-derived E7 protein was prepared as
described and used as a crude cell lysate (17). A highly purified (>95%)
preparation of bacterially produced HPV-16 E7 protein was prepared as
described (18).
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Fig. 1. Series of overlapping peptides GF101-
GF109 that span the HPV16 E7 molecule. Known
murine B epitopes are boxed: promiscuous T-helper
epilope is ringed. The sequence of the synthetic
peptide BT12D that contains three B epitopes and
the T-helper epitope is shown below.
[Ml
GF102
GF105
10 20
MHGDTPTLHgYMLyLQPETtDLYÃ‡
GF109
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NDSSEEED^IDGf^f^QÃ‚EPlOfiAHYNiyTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP
Immunization Protocol. Mice were immunized i.p. with an emulsion
generated by mixing 50 mg of antigen, dissolved or suspended in 0.1 ml of
0.15 M NaCl with 0.1 ml of complete Freund's adjuvant, and boosted at days
14 and 28 with an equal amount of antigen in incomplete Freund's adjuvant.
Sera were obtained from mice at day 42.
Assay of E7 Protein. Tissues for analysis were snap frozen in solid
CO,-ethanol and held at â€”¿70Â°Cfor analysis. Tissues were pulverized in a
chilled mortar and pesile and assayed for HPV-16 E7 and HPV-18 E7 protein
as a control, with the use of an ELISA capture assay standardized on HPV 16
E7 fusion protein essentially as described previously (14), except that extracted
samples were boiled for 5 min with 0.1% SDS prior to analysis, which
stabilizes the E7 protein (data not shown). Limits of E7 protein detection were
established by performing the ELISA capture assay in parallel with serial
dilutions of bacterially synthesized E7 fusion protein that had been purified
and quantitated (see Ret. 14).
Antibody to E7 Protein and Peptides. An ELISA was used to measure
antibody as described previously (16). In brief, peptides and proteins were
dissolved in carbonate buffer (pH 9.4) and allowed to adsorb to 96-well plates.
Plates were blocked with 2% BSA and exposed for l h to sera diluted 1:20 (or
otherwise where stated) in PBS-2% BSA. Plates were washed extensively with
PBS-0.1% gelatin-0.1% Tween 20, exposed to goat anti-mouse immunoglob-
ulin or goat anti-mouse IgG (Sigma Chemical Co., St. Louis, MO), washed
additionally, and developed with 2,2'-azino-bis(3-ethylbenzthiazoline-6-sul-
fonic acid substrate. Absorbance measurements (414 and 620 nm) were as
sessed after 5-30 min of incubation with substrate on a Titertek Multiskan dual
wavelength spectrophotometer (LabSystems, Helsinki. Finland).
DTH to E7 Protein. Mice were given 400 ng pertussigen (CSL, Mel
bourne. Australia) i.v. in 0.1 ml PBS (19) and immediately challenged i.d. in
the left ear with 0.5-2.5 mg protein in 10 /n.1PBS. Ear thickness was assessed
with the use of spring-loaded calipers (Mitutoyo 2046F) 48 and 96 h after
challenge and was reported as the difference between the challenged and the
control ear.
RESULTS
Induced Antibody Response to HPV-16 E7 Protein in Line 19
Mice. To analyze the potential of the aAcryHPV16E6/E7-linel9
(herein referred to as line 19) mice to respond immunologically to E7
protein, young transgenic and nontransgenic animals were immunized
with E7 protein and sera monitored for E7-specific antibodies. These
transgenic mice developed E7-specific antibodies as did E7-immu-
nized nontransgenic mice (Table 1). Furthermore, the transgenic and
nontransgenic mice responded to similar linear epitopes from E7 (Fig.
2A), these epitopes being equivalent to those recognized by sera from
E7-immunized mice of other haplotypes (H-2b, H-2d , //-2s, ff-2k; the
line 19 mice are in the FVB inbred background and are, therefore,
//-2q; Refs. 16, 20). Consistent with these observations, both the
transgenic and nontransgenic mice developed E7-specific antibodies
when immunized with an oligopeptide, BT12D, containing a known
E7-specific T-helper epitope and the above noted E7-specific B cell
epitopes (Table 1). Thus, the humoral responses of transgenic and
nontransgenic mice were indistinguishable from each other.
E7 Protein Expression in the Skin of Line 19 Mice. Self-
tolerance is argued to occur through the recognition of self-peptides
expressed during postnatal development within immunosurveyed sites
in the thymus (central or deletional tolerance) or other tissues (pe
ripheral tolerance). Our E7 immunization studies suggested an ab
sence of central and peripheral tolerance to E7 in the line 19 trans
genic mice. To address whether this absence of tolerance correlated
with an absence in the expression of E7 protein in immunosurveyed
sites in young transgenic mice, we measured E7 protein levels in
various organs of line 19 mice utilizing an ELISA-capture assay
sensitive to 0.05 ng E7/mg cellular protein. No E7 protein was
detected in any tissues from nontransgenic mice (data not shown). E7
protein was found in the eye of line 19 mice at an early age (Table 2).
This was anticipated given that the transgene is under the control of
the aA-crystallin promoter and is actively transcribed in the lens by
day 17 in embryogenesis (4). Expression of E7 protein in the lens,
however, would not be predicted to induce tolerance given that the
lens is an immunoprivileged site. No E7 protein was detected in any
other tissue of young line 19 mice, including the liver, spleen, brain,
stomach, skin and, importantly, the thymus (Table 2; data not shown).
In our previous study, we demonstrated increased levels of E6 and
E7 mRNAs in the abnormal skin and skin cancers in older line 19
mice (12). Skin samples from line 19 mice were, therefore, tested for
E7 protein. Some older (>28 weeks old) mice were found to be
positive for E7 protein in normal and diseased skin, as well as in a skin
Table 1 Induced immune response to E7 proteins and peptides in young line 19 and FVB mice
ImmunogenSalineSalineE7"E7*GST-E7GST-E7BT12DBT12DmAb
a ETMouse
strain
(no. ofmice)Line
19(3)FVB
(3)Line
19(3)FVB
(3)Line
19(3)FVB
(2)Line
19(4)FVB
(4)Mean
absorbance units (Â±1SEM)" for substraleantigenBSA0.002
Â±0.0000.003
+0.0010.001
Â±0.0000.005
Â±0.0010.001
Â±0.0000.001
Â±0.0000.001
Â±0.0000.001
+0.0000.001E70.006
Â±0.0010.003
Â±0.0010.027
Â±0.0040.070
Â±0.0370.347
Â±0.0220.350
Â±0.0260.1
94Â±0.0030.157
+0.0230.205GST-E70.018
+0.0050.005
Â±0.0010.055
Â±0.0140.095
Â±0.0390.481
Â±0.0180.372
Â±0.0070.21110.0070.162
+0.0320.243MS2-E70.041+0.0150.016
+0.0030.077
Â±0.0200.095
Â±0.0380.354
Â±0.0280.384
+0.0680.172
Â±0.0170.1
05Â±0.0230.171BT12D0.002
Â±0.0000.002
Â±0.0000.015
Â±0.0010.066
+0.0070.1
19Â±0.0530.189
+0.1500.229
Â±0.0120.222
Â±0.0100.221
" Absorbance units (414-620 nm). Note the small but significant difference in reaclivity of the saline/line 19 versus saline/FVB mouse sera to E7 substrates was not reproduced
with additional bleeds from these same mice.
' Produced using a baculovirus vector.
' Control result with E7-specific mAb 6D (15) used at 1:1000.
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some older line 19 mice and, particularly, in older line 19 mice with
skin disease (Fig. 3; see also Fig. 2B for data on smaller groups of
additional animals). This correlation between skin disease and serum
antibody to E7 protein was significant (Table 3; P = 0.007) and
reproducible among multiple independent ELISA assays on the same
group of sera (data not shown). Thus, spontaneous humoral responses
to E7 protein occur in the line 19 mice and correlate with the presence
of skin disease.
The properties of the E7-reactive sera from these unimmunized line
19 mice differed from that of E7-immunized syngeneic mice in two
respects: (a) the E7-reactive sera from unimmunized line 19 mice had
antibody titers significantly lower than that in sera from E7 immu
nized mice. This is deduced from the reproducible difference in the
strength of ELISA readouts against GST-E7 substrate for these two
populations of animals as reported in Fig. 3 (mean absorbance units
for the seven unimmunized older animals with skin disease = 0.180;
note a similar mean value of 0.130 was found for a smaller group of
3 animals evaluated in Fig. 2B) versus Table 1 (mean absorbance
units for E7-immunized line 19 mice = 0.481); and (b) the B-cell
epitopes on E7 recognized by the E7-reactive, unimmunized line 19
mice mapped to the COOH terminus of E7 (Fig. 2B), and, therefore,
Skindisease differ from the NH2 terminus-specific epitopes predominantly recog
nized in E7-immunized FVB mice (Fig. 2A).
Spontaneous Delayed-Type Hypersensitivity to E7 Protein. Ul
timately, we are interested in understanding whether immune re
sponses against E7, spontaneous or induced, can provide protection
against the development of HPV-associated neoplasia. Such protec
tive immune responses are thought to primarily rest in the cellular arm
of the immune system. To test whether spontaneous cellular immune
H No skin disease
Antigen
Fig. 2. Serum reactivity to HPV 16 E7 protein and peptides by ELISA. A, groups of
three 6-8-week-old line 19H or FVB mice, as indicated, immunized with the stated
antigen in complete Freund's adjuvant. B, groups of unimmunized 26-52-week-old line
19 mice with skin disease (n = 5), and littermate line 19 controls without skin disease
(n = 3). Reactivity was shown to include antibody of IgG isotype with the use of
isotype-specific antisera in the ELISA. Columns, mean; bars, SEM.
Table 2 Immunoreactive E7 protein in the tissues of line 19 mice
A 03 H
e
9
n
Young mice (4-7 weeks) Old mice (26-52 weeks)
TissueEyeEye
tumorNormal
skinDiseased
skinSkin
tumorsn"i/rNA0/20NANAÂ¡Â£7*
n"60
NT2/56/227/141/3ÃŒE7*3.8-5.20.7-13.90.3-11.50.74
" n, number of positive samples/total number of samples tested; NA, not available; NT,
not tested.
Results are expressed as ng immunoreactive E7 protein (iE7) per mg cellular protein
in positive samples. The lower detection limit of the assay is 0.05 ng iE7/mg cellular
protein.
' Results from four eyes assayed together.
tumor. The highest levels of E7 observed in the skin of line 19 mice
were 4-fold lower than levels in the CaSki cervical carcinoma cell line
(50 Â±10 ng E7/mg cell protein). In contrast, skin samples from young
(7-13-week-old) line 19 mice had undetectable E7 protein. Thus,
expression of detectable levels of E7 protein was found to occur at a
nonimmunoprivileged site specifically in older mice.
Spontaneous Antibody Response to E7 Protein and Peptides.
Given the absence of tolerance in line 19 mice and the adult onset
expression of E7 protein in the skin, we addressed whether these
transgenic mice developed spontaneous immune responses to endog-
enously expressed E7 protein as a function of age. Humoral immune
responses to E7 were assessed in young (4-7 weeks) and older
(26-30 weeks) line 19 mice. E7-specific antibodies were found in
Disease
positive
Disease
negative
Fig. 3. Distribution of E7-specific ELISA readings for sera from older unimmunized
line 19 mice. Points, absorbance measurements (414-620 nm) for sera reactivity to
GST-E7 substrate. The mean background absorbance measurement for these sera (to BSA
substrate) was 0.033 Â±0.009. Skin disease was scored by the presence of hair loss, with
or without papillomatosis or carcinoma. See Table 3 for correlation between skin disease
and E7 reactivity.
Table 3 Associations between skin disease and serum antibody to E7 protein
in older line 19 mice"
Serum E7 antibody
Skin disease Positive Negative
Positive
Negative
2
12
" Number of animals in each group was determined based on the E7-reactivity data
presented in Fig. 3. The correlation between E7 positivity of sera and skin disease had a
calculated significance of P = 0.007 (Fischer's exact test). Sera were considered E7
reactive (serum E7 antibody positive) if they had ELISA readings that were 3-fold over
background. The average of the ratio (E7-specific reactivity/BSA-specific reactivity) was
5.4 for the E7-reactive (positive) animals and 2.0 for the E7-nonreactive (negative)
animals.
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Table 4 DTH to HPV-16 E7 protein in \oung und old line 19 transgenic mice
and FVB controls
A Ear thickness (mm X IO2 Â±1 SEM),(n)"Ear
challengeGST-E7
GST
SalineOld
line1915
Â±4 (4)''
2 Â±2 (3)
-1 Â±1 (4)Young
line193
Â±1 (4)
3 Â±1(4)2
Â±2 (4)Old
FVB3
Â±1 (4)
6 Â±3 (3)
0 Â±1 (4)
" Average of the difference between the challenged and control ear at day 4.11. number
of mice/group. As positive controls, two E7-immunized line 19 mice gave DTH responses
(A ear thickness) of 15.
f < 0.01 compared with the control groups.
responses to endogenous E7 protein occur in our line 19 transgenic
mice, experiments measuring DTH to HPV-16 E7 protein were per
formed, with the use of an ear challenge assay (Table 4). DTH is
thought to represent antigen-specific cytokine-mediated inflamma
tion, particularly involving Thl type cytokines, in this case in re
sponse to endogenous E7 protein. DTH responses to E7 have been
previously noted in mice that had received grafts of E7-positive cells
(21). In our hands, positive DTH responses peaking at 48-96 h and
specific to GST-E7 protein were observed in 3 of 4 older line 19 mice.
Two of these DTH-positive animals also had skin disease and E7-
specific serum antibodies. None of the younger mice, or the nontrans-
genic controls, developed DTH responses against E7. These results
indicate that unimmunized older line 19 mice may develop a cellular
immune response to E7 protein.
DISCUSSION
In this study we have demonstrated that a line of mice transgenic
for HPV-16 E6 and E7 oncogenes develop spontaneous immune
responses to E7 that correlate with the presence of skin disease.
Unlike in E7-immunized mice challenged with transplantable tumors
transduced to express E6 or E7 (11, 22, 23), the line 19 mice with
spontaneous immune responses to E7 are not protected against the
development of HPV-16-associated cancer. This finding parallels
observations with cervical cancer patients in which there is a weak
and inconsistent antibody response to E7 protein (24). We therefore
believe that these mice may provide a valuable tool with which to
study the immunobiology of HPV-16-associated cancer.
We were surprised initially to find an absence of tolerance to the E7
transgene in the line 19 mice. Determinants of the development of
tolerance or immune responsiveness to transgenic proteins are uncer
tain. Deletional B- and/or T-cell tolerance is observed generally when
the protein is expressed in a wide range of tissues from a strong
constitutive promoter (25), whereas functional silencing of T or B
cells (anergy; Ref. 26) or developing immunity (27, 28) has been
observed in transgenic models in which there is tissue-specific ex
pression of the transgene protein. In a number of transgenic mouse
models, development of immunity or tolerance to the transgene prod
uct has been held to be a consequence of the level and/or timing of
transgene expression (29, 30, 31). In this regard, the absence of
tolerance to E7 in the line 19 mice correlated with an absence of
detectable E7 protein expression in neonatal thymus (data not shown)
and in all other tissues tested from young animals with the exception
of the lens, an immunoprivileged site. The lack of E7 expression in
immunosurveyed tissues during the time when deletional tolerance
occurs provides one likely explanation for the absence of B- and
T-cell tolerance in these animals.
We observed a correlation between skin disease and spontaneous
immune responses to E7 protein in older line 19 mice (Table 3). The
adult onset immune responses may reflect the observed increases in
the levels of E7 protein expressed in immunosurveyed tissues
(Table 2). However, the molecular mechanisms for this increased
expression of E7 protein are not known at this time. Possible mech
anisms include amplification of the transgenes, increased transcription
of E7, or changes in the stability of E7 protein. Alternatively, the adult
onset immune responses may represent an altered sensitivity of the
immune system to presentation of E7-specific epitopes, perhaps
mediated by cytokine induction resulting from skin wounding.
Despite the evidence for spontaneous humoral and cellular immune
responses to E7 (Fig. 3; Tables 3 and 4), the line 19 mice develop
squamous cell carcinomas in which the E7 oncoprotein is expressed
(12). Thus, the spontaneous immune responses are not protective. It is
clear from other studies that mice can develop protective immunity
when E7 is presented optimally (11, 22, 23). The lack of protective
immunity in the line 19 mice may reflect the nature of E7 presentation
by the skin or tumor cells to the immune system. For instance, were
E7 presented in line 19 mice by E7-positive keratinocytes (Table 2),
which are nonprofessional antigen-presenting cells, this presentation
may be suboptimal. We found the strength of the E7-specific spon
taneous humoral immune responses in line 19 mice (Table 3) to be
well below that seen in mice immunized with E7 (Table 1). This low
level spontaneous immune response may not be sufficient to provide
protective immunity. Additionally, the E7 reactive sera from the older,
unimmunized line 19 animals predominantly recognized linear
epitopes at the COOH terminus of E7 (GF107, GF108, and GF109;
Fig. 2B), a region likewise recognized by sera from CBA (H-2k) mice
seeded with mouse L fibroblasts expressing the E7 gene (20). In
contrast, the E7-specific epitopes (residing within peptides GF101,
GF102, GF105, and GF106) strongly recognized by the E7-immu-
nized transgenic and nontransgenic mice (Fig. 2A) lie in the NH2
terminus of E7 protein. These findings suggest differential processing
or presentation of E7 protein by professional versus nonprofessional
antigen-presenting cells, and this difference could contribute to the
absence of protective immunity. A better understanding of the immu
nobiology of the line 19 mice may provide insight into how the
immune system, when faced with the suboptimal presentation of
papillomaviral antigens, can be induced to generate protective immu
nity against HPV-associated cancer.
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